The estimated Net Worth of W Anthony Vernon is at least $12.4 Million dollars as of 4 June 2024. Mr. Vernon owns over 964 units of NovoCure Ltd stock worth over $2,840,073 and over the last 10 years he sold NVCR stock worth over $9,126,030. In addition, he makes $434,303 as Lead Independent Director at NovoCure Ltd.
William has made over 12 trades of the NovoCure Ltd stock since 2016, according to the Form 4 filled with the SEC. Most recently he sold 964 units of NVCR stock worth $23,030 on 4 June 2024.
The largest trade he's ever made was exercising 249,085 units of NovoCure Ltd stock on 13 May 2016 worth over $42,344. On average, William trades about 15,293 units every 63 days since 2015. As of 4 June 2024 he still owns at least 164,833 units of NovoCure Ltd stock.
You can see the complete history of Mr. Vernon stock trades at the bottom of the page.
William A. Vernon serves as Lead Independent Director of the Company. He has been a director of Novocure since 2006, serving on our compensation committee since 2012 and as chairperson of our nominating and corporate governance committee since 2015. Mr. Vernon served as the Chief Executive Officer of the Kraft Foods Group, a food products company, from 2012 to 2014 and served as a senior advisor through May 2015. From 2009 to 2011, Mr. Vernon served as the President of Kraft Foods North America and as an Executive Vice President of Kraft Foods. From 2006 to 2009, Mr. Vernon served as the healthcare industry partner for Ripplewood Holdings, a private equity firm. From 1982 to 2005, Mr. Vernon worked for Johnson & Johnson in a variety of leadership roles, including as Company Group Chairman of DePuy Orthopaedics, President of Centocor Biologics, President of McNeil Consumer Products and Nutritionals, and President of The Johnson & Johnson-Merck Joint Venture. Mr. Vernon currently serves on the boards of Axovant Sciences, Intersect ENT Inc. and The WhiteWave Foods Company, and he previously served on the board of the Kraft Foods Group from 2012 to 2015. Mr. Vernon holds a B.A. in history from Lawrence University and an M.B.A. from Northwestern University’s Kellogg School of Management.
As the Lead Independent Director of NovoCure Ltd, the total compensation of William Vernon at NovoCure Ltd is $434,303. There are 11 executives at NovoCure Ltd getting paid more, with William Doyle having the highest compensation of $8,286,100.
William Vernon is 64, he's been the Lead Independent Director of NovoCure Ltd since 2016. There are 3 older and 21 younger executives at NovoCure Ltd. The oldest executive at NovoCure Ltd is Prof. Yoram Palti, 83, who is the Founder & CTO.
W's mailing address filed with the SEC is C/O NOVOCURE INC., 1550 LIBERTY RIDGE DRIVE, SUITE 115, WAYNE, PA, 19087.
Over the last 9 years, insiders at NovoCure Ltd have traded over $237,132,855 worth of NovoCure Ltd stock and bought 164,174 units worth $2,198,429 . The most active insiders traders include Asaf Danziger, William Fwfd Ventures Fund ..., and Michael J. Ambrogi. On average, NovoCure Ltd executives and independent directors trade stock every 7 days with the average trade being worth of $853,350. The most recent stock trade was executed by Ashley Cordova on 2 August 2024, trading 688 units of NVCR stock currently worth $13,856.
we are a commercial-stage oncology company developing a novel, proprietary therapy called tumor treating fields, or ttfields, for the treatment of solid tumor cancers. we count on the contributions of our talented team members who are committed to improving the lives of cancer patients. here at novocure, cancer patients and their families are – and have always been – at the core of our mission. we expect our colleagues to excel, and in return, we invest in their professional growth and personal well-being. we seek high performers who thrive in fast-paced environments and are inspired by making a difference in cancer care. we offer employment opportunities in the u.s., europe and asia.
NovoCure Ltd executives and other stock owners filed with the SEC include: